Tyr930
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr930  -  EphA2 (human)

Site Information
EHFMAAGyTAIEKVV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457516

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 ) , microscopy-colocalization with upstream kinase ( 2 ) , mutation of modification site ( 2 , 16 ) , phospho-antibody ( 2 , 16 ) , western blotting ( 2 , 16 )
Disease tissue studied:
brain cancer ( 8 ) , astrocytoma ( 8 ) , colorectal cancer ( 7 , 18 ) , colorectal carcinoma ( 7 , 18 ) , esophageal cancer ( 15 ) , esophageal carcinoma ( 15 ) , gastric cancer ( 4 , 5 , 6 , 17 ) , gastric carcinoma ( 4 , 5 , 6 , 17 ) , leukemia ( 11 , 12 , 13 , 14 ) , chronic myelogenous leukemia ( 11 , 12 , 13 , 14 ) , lung cancer ( 9 , 17 ) , non-small cell lung cancer ( 9 , 17 ) , non-small cell lung adenocarcinoma ( 9 ) , ovarian cancer ( 10 ) , ovarian epithelial carcinoma ( 10 ) , rhabdomyosarcoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative upstream phosphatases:
PTPRF (human) ( 2 )

Downstream Regulation
Effects of modification on EphA2:
enzymatic activity, induced ( 16 ) , molecular association, regulation ( 1 , 2 , 16 )
Effects of modification on biological processes:
cell differentiation, altered ( 16 ) , cell motility, induced ( 2 )
Induce interaction with:
GRB2 (human) ( 1 ) , NCK1 (human) ( 2 ) , PIK3R1 (human) ( 16 ) , SHIP-2 (human) ( 1 ) , VAV3 (human) ( 16 )

References 

1

Borthakur S, et al. (2014) Binding and function of phosphotyrosines of the Ephrin A2 (EphA2) receptor using synthetic sterile α motif (SAM) domains. J Biol Chem 289, 19694-703
24825902   Curated Info

2

Lee H, Bennett AM (2013) Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol Cell Biol 33, 1430-41
23358419   Curated Info

3

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

4

Rikova K (2012) CST Curation Set: 13326; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Mulhern D (2011) CST Curation Set: 12645; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Mulhern D (2011) CST Curation Set: 12853; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Possemato A (2011) CST Curation Set: 11911; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Possemato A (2011) CST Curation Set: 11915; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Ren H (2011) CST Curation Set: 11783; Year: 2011; Biosample/Treatment: cell line, RP100/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Possemato A (2010) CST Curation Set: 9956; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Possemato A (2010) CST Curation Set: 9858; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Possemato A (2010) CST Curation Set: 9859; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Possemato A (2010) CST Curation Set: 9856; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Tucker M (2010) CST Curation Set: 9225; Year: 2010; Biosample/Treatment: cell line, Kyse140/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Fang WB, et al. (2008) Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem 283, 16017-26
18387945   Curated Info

17

Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 692-7
18180459   Curated Info

18

Li Y (2006) CST Curation Set: 1265; Year: 2006; Biosample/Treatment: cell line, SW620/TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Zhang Y, et al. (2005) Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4, 1240-50
15951569   Curated Info